Globus Medical (GMED) vs Stevanato Group S.p.A. (STVN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Globus Medical (GMED) has outperformed Stevanato Group S.p.A. (STVN) over the past year, gaining 21.4% versus a loss of 21.8%. Over five years, GMED leads with a -4.1% price change compared with -21.0% for STVN. Globus Medical is the larger company by market cap ($10.02 billion vs $5.30 billion), about 1.9 times the size.
On valuation, Globus Medical trades at a lower forward P/E (13.8x vs 23.2x for Stevanato Group S.p.A.).
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | GMED | STVN |
|---|---|---|
| Share price | $74.65 | $19.40 |
| Market cap | $10.02B | $5.30B |
| 1-day change | +1.80% | +0.99% |
| YTD return | -16.01% | -4.52% |
| 1-year return | +21.37% | -21.85% |
| 5-year return | -4.06% | -21.01% |
| P/E ratio (TTM) | 19.14 | 34.04 |
| Forward P/E | 13.83 | 23.25 |
| EPS (TTM) | $3.90 | $0.57 |
| Dividend yield | 0.00% | 0.32% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $2.94B | — |
| Revenue growth (YoY) | +16.65% | — |
| Net income (latest FY) | $537.87M | — |
| Gross margin | 67.41% | — |
| Operating margin | 16.33% | — |
| Net margin | 18.30% | — |
| 52-week high | $101.40 | $27.99 |
| 52-week low | $56.50 | $12.89 |
| Distance from 52-week high | -26.38% | -30.69% |
| Analyst consensus | buy | buy |
| Avg. price target upside | +35.19% | +27.22% |
| Average volume | 1.51M | 369.25K |
| Shares outstanding | 111.83M | 49.83M |
| Employees | 6,000 | 6,010 |
| Sector | Health Care | Health Care |
| Industry | Medical/Dental Instruments | Medical/Dental Instruments |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- GMED has outperformed STVN by 43.2 percentage points over the past year.
- Stevanato Group S.p.A. trades at a higher earnings multiple (34.0x vs 19.1x trailing P/E).
About Globus Medical
GMED stock →Globus Medical, Inc. develops and commercializes healthcare solutions for patients with musculoskeletal disorders in the United States and internationally.
Health Care · Medical/Dental Instruments · 6,000 employees
About Stevanato Group S.p.A.
STVN stock →Stevanato Group S.p.A. engages in the design, production, and distribution of products and processes to provide solutions for biopharma and healthcare industries in Europe, the Middle East, Africa, North America, South America, and the Asia Pacific.
Health Care · Medical/Dental Instruments · 6,010 employees
GMED vs STVN FAQ
Which is bigger, Globus Medical or Stevanato Group S.p.A.?
Globus Medical (GMED) is larger, with a market capitalization of $10.02B compared with $5.30B for Stevanato Group S.p.A. (STVN).
Which stock has performed better over the past year, GMED or STVN?
GMED returned +21.37% over the past 12 months, compared with -21.85% for STVN (price return, excluding dividends). Past performance does not predict future results.
Which has the lower P/E ratio, GMED or STVN?
GMED has the lower trailing P/E at 19.1, versus 34.0 for STVN. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.
Which pays a higher dividend, Globus Medical or Stevanato Group S.p.A.?
Stevanato Group S.p.A. pays a dividend yielding 0.32%, while Globus Medical does not currently pay a regular dividend.
Are Globus Medical and Stevanato Group S.p.A. in the same industry?
Yes. Both are classified in the Medical/Dental Instruments industry within the Health Care sector.